Akili raises extra $13M ahead of FDA decision on prescription video game for ADHD

AKL-T01
Akili recently filed for 510(k) clearance for its prescription, tablet-based video game for ADHD after it met its endpoint in a randomized trial in December 2017. (Akili)

Akili Interactive has gathered an additional $13 million to fund its prescription video game treatments, bringing its series C total up to $68 million. Meanwhile, it is awaiting an FDA clearance decision on its recently filed digital therapeutic for pediatric ADHD.

Launched in May, the initial round was led by Temasek and included Amgen Ventures and M Ventures, the VC fund of Merck KGaA, as well as Baillie Gifford, JAZZ Venture Partners, Canepa Advanced Healthcare Fund and Brooklands Capital Strategies.

The Boston-based company’s latest investors were CLSA, Omidyar Technology Ventures, Fearless Ventures and Digital Garage Group, which includes DG Incubation and DG Daiwa Ventures.

WEBINAR

Webinar: The Key to Continuous Compliance for Medical Device Software Developers

Risk is not an option in medical device software development. You need to mitigate time-to-market, FDA, and security risks, or you could be facing a costly recall or software update. Attend this webinar to learn how to use static analysis to ensure continuous compliance with industry standards and regulatory requirements, improve security for increasingly connected medical devices, and enforce corporate and industry coding rules and best practices.

“Both Akili and the broader field of digital medicine have been advancing at a significant pace,” Akili CEO Eddie Martucci, Ph.D., said in a statement. If cleared by the agency, the company’s lead product, AKL-T01, would be the first prescription video game and the first digital medicine for children with ADHD.

RELATED: Akili's video game therapy hits goal in pivotal ADHD trial

“This additional backing from investors will help us significantly drive forward the development and deployment of our technology platform toward our goal of having a major impact in millions of patients and toward fulfilling the immense promise of digital medicine,” Martucci said.

In clinical trial results posted last December, Akili’s tablet-based video game improved attention and control in children ages eight to 12 with ADHD after four weeks, compared to children who played a different game without embedded stimuli designed to engage specific areas of the brain.

Akili is also developing interactive, digital treatments in major depressive disorder, autism spectrum disorder, multiple sclerosis and inflammatory diseases, and anticipates phase 2 results in MDD by the end of the year.

Suggested Articles

Illumina plans to help map thousands of years of DNA fragments in a hunt for clues into today’s mental health issues and neurological conditions.

Alongside a notice from the FDA, Medtronic disclosed a cybersecurity vulnerability in its defibrillators and resynchronization therapy hardware.

Liquid biopsy developer Epic Sciences has brought on Myriad Genetics’ oncology chief, Lloyd Sanders, to be its new president and CEO.